WO2006076222A3 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations Download PDF

Info

Publication number
WO2006076222A3
WO2006076222A3 PCT/US2006/000447 US2006000447W WO2006076222A3 WO 2006076222 A3 WO2006076222 A3 WO 2006076222A3 US 2006000447 W US2006000447 W US 2006000447W WO 2006076222 A3 WO2006076222 A3 WO 2006076222A3
Authority
WO
WIPO (PCT)
Prior art keywords
carrier
active ingredient
formulation
solid pharmaceutical
agent
Prior art date
Application number
PCT/US2006/000447
Other languages
French (fr)
Other versions
WO2006076222A2 (en
Inventor
Michael K Taylor
Original Assignee
Glaxo Group Ltd
Michael K Taylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Michael K Taylor filed Critical Glaxo Group Ltd
Publication of WO2006076222A2 publication Critical patent/WO2006076222A2/en
Publication of WO2006076222A3 publication Critical patent/WO2006076222A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Abstract

The invention relates to an inhalable solid pharmaceutical formulation comprising (a) an anti-cholinergic agent, (b) a carrier and (c) a ternary agent that is a sugar ester, an inhaler comprising such a formulation, a method of reducing or inhibiting chemical interaction between an active ingredient substance and a carrier susceptible to chemical interaction, a method of reducing or inhibiting chemical degradation of an active ingredient substance in a formulation comprising a carrier and an active ingredient substance, a method for the treatment of a reversible airways obstruction by administering to a patient in need thereof the inhalable solid pharmaceutical formulation, and a method of preparing a solid pharmaceutical preparation comprising combining (a) an anti-cholinergic agent, (b) a carrier and (c) a ternary agent that is a sugar ester.
PCT/US2006/000447 2005-01-10 2006-01-06 Pharmaceutical formulations WO2006076222A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64266605P 2005-01-10 2005-01-10
US60/642,666 2005-01-10

Publications (2)

Publication Number Publication Date
WO2006076222A2 WO2006076222A2 (en) 2006-07-20
WO2006076222A3 true WO2006076222A3 (en) 2006-12-21

Family

ID=36678092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/000447 WO2006076222A2 (en) 2005-01-10 2006-01-06 Pharmaceutical formulations

Country Status (1)

Country Link
WO (1) WO2006076222A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697719B2 (en) 2009-08-07 2014-04-15 Generics [Uk] Limited Anhydrate of tiotropium bromide
TR200907237A2 (en) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropium dry powder combination
WO2011095800A2 (en) * 2010-02-02 2011-08-11 Generics [Uk] Limited Analytical methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010038858A1 (en) * 1994-08-04 2001-11-08 Roser Bruce J. Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US6551622B1 (en) * 1999-07-12 2003-04-22 Quadrant Holdings Cambridge, Ltd Dry powder compositions
US20050201949A1 (en) * 2003-07-11 2005-09-15 Monteith Michael J. Pharmaceutical formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010038858A1 (en) * 1994-08-04 2001-11-08 Roser Bruce J. Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US6551622B1 (en) * 1999-07-12 2003-04-22 Quadrant Holdings Cambridge, Ltd Dry powder compositions
US20050201949A1 (en) * 2003-07-11 2005-09-15 Monteith Michael J. Pharmaceutical formulations

Also Published As

Publication number Publication date
WO2006076222A2 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
WO2007047948A3 (en) Intranasal administration of rapid acting insulin
WO2010015665A3 (en) Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
WO2007123945A3 (en) Mechanical single dose intrapulmonary drug delivery devices
DK1658047T3 (en) Spray dry amorphous powder with low residual moisture and excellent storage stability
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
WO2007123955A3 (en) Stable hydroalcoholic oral spray formulations and methods
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
WO2002074247A8 (en) Pharmaceutical formulations for sustained release
WO2006044421A3 (en) Cardiac safe, rapid medication delivery
NO20064161L (en) Pharmaceutical formulations for dry powder inhalers comprising an active ingredient with low dosage strength
KR20190108104A (en) Use of Sublingual Dexmedetomidine for Treatment of Anxiety
WO2009127974A3 (en) Pharmaceutical formulation for treating cardiovascular disease
CN108348894A (en) For compound activating and the ozonolysis of ozone degradation
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
WO2005044226A3 (en) Lipid formulations for spontaneous drug encapsulation
WO2008093075A3 (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
WO2009136408A4 (en) Synergistic pharmaceutical cocrystals
WO2007146293A3 (en) Improved composition and method for taste masking
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
EP1797897A4 (en) Medicinal composition containing meltrin antagonist
JP2018532710A (en) Nitric oxide inhalation therapy for infants with bronchiolitis
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
CN116507327A (en) Chewable formulations
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06717621

Country of ref document: EP

Kind code of ref document: A2